期刊文献+

HPLC法测定氨基葡萄糖类药物的有关物质 被引量:3

Determination of the Related Substance in Glucosamine by HPLC
下载PDF
导出
摘要 目的:建立高效液相色谱法测定氨基葡萄糖类药物的有关物质的方法,为质量标准提高提供参考。方法:采用高效液相色谱-紫外检测法,色谱柱为岛津Inertsil ODS-3柱(150 mm×4.6 mm,3μm),以庚烷磺酸钠溶液(取庚烷磺酸钠0.50 g,溶解至适量水中,加0.5 ml磷酸和1 mol·L-1的氢氧化钾溶液4 ml,加水至1 000 ml)-乙腈(96∶4)为流动相,流量:1.0 ml·min-1,检测波长为195 nm,柱温:30℃,进样量:20μl。以2-甲基吡嗪作为外标对照品,测定氨基葡萄糖类药物的有关物质的限量。结果:2-甲基吡嗪在1.0~10.0μg·ml-1范围内呈良好的线性关系(r=1.000 0),平均回收率为99.0%,RSD为0.8%(n=9)。结论:该法能有效分离氨基葡萄糖与其降解杂质2,5-果糖嗪、2,5-脱氧果糖嗪,用吸收系数相当的2-甲基吡嗪作为外标对照品控制单个杂质和总杂质的限量,方法简便、准确,专属性强,适用于氨基葡萄糖类药物的质量控制。 Objective: To establish an HPLC method for determining the related substance in glucosamine. Methods: HPLC-UV was applied. An Inertsil ODS-3( 150 mm×4.6 mm,3 μm) column was used and the mobile phase was 0.50 g sodium heptanesulfonate dissolved in water,and 0.5 ml phosphoric acid and 4 ml potassium hydroxide solution( 1 mol·L-1) diluted by water to 1 000 ml-acetonitrile( 96 ∶4). The flow rate was 1.0 ml·min-1,and the detection wavelength was set at 195 nm. Results: A good linear range for 2-methylpyrazine was 1.0-10.0 μg·ml-1( r= 1.000 0),and the average recovery was 99.0%( RSD = 0.8%,n = 9). Conclusion: The method can effectively separate glucosamine from its impurities 2,5-fructosazine and 2,5-Deoxyfructosazine. 2-Methylpyrazine with the same absorption coefficient is used as the external reference for the determinations of single impurity and the total impurities,and the method is simple,accurate and reliable,which is suitable for the quantity control of glucosamine.
作者 但晓梦 郭江红 姜红 Dan Xiaomeng;Guo Jianghong;Jiang Hong(Hubei Institute for Drug Control,Hubei Institute for Biological Products Control,Wuhan430000,China)
出处 《中国药师》 CAS 2019年第7期1370-1374,共5页 China Pharmacist
关键词 高效液相色谱法 氨基葡萄糖 杂质分析 质量控制 HPLC Glucosamine Impurity analysis Quality control
  • 相关文献

参考文献5

二级参考文献59

  • 1李海英.HPLC-ELSD检测盐酸氨基葡萄糖中的有关物质[J].华西药学杂志,2008,23(2):229-230. 被引量:6
  • 2栗艳,田云,关月,奚苗苗,常瑛,文爱东.LC-MS/MS法测定人血浆中硫酸氨基葡萄糖浓度及其药动学研究[J].中国药房,2011,22(14):1282-1285. 被引量:2
  • 3戴冽.氨基葡萄糖治疗骨关节炎的现状[J].中国新药与临床杂志,2004,23(7):455-458. 被引量:24
  • 4Amin AR, Attur MG, Abramson SB. Regulation of nitric oxide and inflammatory mediators in human ostecarthritis-affeeted cartilage: implication for pharmacological intervention[A]. In: Rubanyi GM ed. The Pathophisiology and Clinical Application of Nitric Oxide[M]. Newwark:Harwood, 1999,397-413.
  • 5Vincenti MP,Brinckerhoff CE.Arthritis Res,2001;3(6):381-388.
  • 6Gouze JN,Bianchi A,Becuwe P,et al.FEBS Lett,2002;510(3):166-170.
  • 7Largo R,Alvarez-Soria MA,Diez-Ortego I,et al.Ostecarthritis Cartilage,2003;11(4):290-298.
  • 8Shikhman AR,Kuhn K,Alaaeddine N,et al.J Immunol,2001;166(8):5155-5160.
  • 9Hoffer LJ,Kaplan LN,Hamadeh MJ,et al.Metabolism,2001;50(7):767-770.
  • 10Piperno M,Reboul P,Hellio-Le-Graverrand MP,et al.Osteoarthritis Cartilage,200;8(3):207-212.

共引文献53

同被引文献18

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部